Christian Carrie1, Nicolas Magné2, Patricia Burban-Provost3, Paul Sargos4, Igor Latorzeff5, Jean-Léon Lagrange6, Stéphane Supiot7, Yazid Belkacemi8, Didier Peiffert9, Nedla Allouache10, Bernard M Dubray11, Stéphanie Servagi-Vernat12, Jean-Philippe Suchaud13, Gilles Crehange14, Stéphane Guerif15, Meryem Brihoum16, Nicolas Barbier17, Pierre Graff-Cailleaud18, Alain Ruffion19, Sophie Dussart20, Céline Ferlay20, Sylvie Chabaud20. 1. Radiotherapy Department, Léon Bérard Center, Lyon, France; CNRS UMR 5220, INSERM U1044, INSA, University of Lyon, Lyon, France. Electronic address: christian.carrie@lyon.unicancer.fr. 2. Cellular and Molecular Radiobiology, Lucien Neuwirth Cancer Institute, and Institute of Nuclear Physics of Lyon, Lyon-Sud Faculty of Medicine, Lyon, France. 3. private hospital of Cotes D'armor, Plerin, France. 4. Radiotherapy Department, Bergonié Institute, Bordeaux, France. 5. Clinique Pasteur Groupe Oncorad Garonne, Toulouse, France. 6. Henri Mondor Breast Center, Créteil, France. 7. René Gauducheau cancer Institute, Nantes, France. 8. Department of Radiation Oncology and Henri Mondor Breast Center, University of Paris-Est, Créteil, France. 9. Lorraine Cancer Institute, Alexis Vautrin Cancer Center, Université de Lorraine, Faculté de Médecine, Vandoeuvre-les-Nancy, France. 10. François Baclesse Cancer Center, Caen, France. 11. Henri Becquerel Cancer Center, Rouen, France. 12. Jean Godinot Institute, Reims, France. 13. Radiotherapy Department, Roanne hospital center, Roanne, France. 14. Georges-François Leclerc Cancer Center, Dijon, France. 15. University hospital of Poitiers, Poitiers, France. 16. UNICANCER, Paris, France. 17. Catalan Cancer Center, Perpignan, France. 18. University Institute of Cancer Toulouse-Oncopôle, Toulouse, France. 19. Urology Department, Hospices Civils de Lyon, Pierre-Bénite, France. 20. Biostatistics Unit, Clinical Research and Innovation Department, Léon Bérard Cancer Centre, Lyon, France.
Abstract
BACKGROUND:Radiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone. METHODS: GETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed adenocarcinoma of the prostate (but no previous androgen suppression or pelvic radiotherapy), stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx according to the tumour, node, metastasis (TNM) staging system, whose prostate-specific antigen (PSA) concentration increased from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL after radical prostatectomy, without evidence of clinical disease. Patients were assigned through central randomisation (1:1) to short-term androgen suppression (subcutaneous injection of 10·8 mg goserelin on the first day of irradiation and 3 months later) plus radiotherapy (3D conformal radiotherapy or intensity modulated radiotherapy of 66 Gy in 33 fractions, 5 days a week for 7 weeks) or radiotherapy alone. Randomisation was stratified using a permuted block method (block sizes of two and four) according to investigational site, radiotherapy modality, and prognosis. The primary endpoint was progression-free survival in the intention-to-treat population. This post-hoc one-shot data collection done 4 years after last data cutoff included patients who were alive at the time of the primary analysis and updated long-term patient status by including dates for first local progression, metastatic disease diagnosis, or death (if any of these had occurred) or the date of the last tumour evaluation or last PSA measurement. Survival at 120 months was reported. Late serious adverse effects were assessed. This trial is registered on ClinicalTrials.gov, NCT00423475. FINDINGS: Between Oct 19, 2006, and March 30, 2010, 743 patients were randomly assigned, 374 toradiotherapy alone and 369 to radiotherapy plus goserelin. At the time of data cutoff (March 12, 2019), the median follow-up was 112 months (IQR 102-123). The 120-month progression-free survival was 64% (95% CI 58-69) for patients treated with radiotherapy plus goserelin and 49% (43-54) for patients treated with radiotherapy alone (hazard ratio 0·54, 0·43-0·68; stratified log-rank test p<0·0001). Two cases of secondary cancer occurred since the primary analysis, but were not considered to be treatment related. No treatment-related deaths occurred. INTERPRETATION: The 120-month progression-free survival confirmed the results from the primary analysis. Salvage radiotherapy combined with short-term androgen suppression significantly reduced risk of biochemical or clinical progression and death compared with salvage radiotherapy alone. The results of the GETUG-AFU 16 trial confirm the efficacy of androgen suppression plus radiotherapy as salvage treatment in patients with increasing PSA concentration after radical prostatectomy for prostate cancer. FUNDING: The French Health ministry, AstraZeneca, la Ligue Contre le Cancer, and La Ligue de Haute-Savoie.
RCT Entities:
BACKGROUND: Radiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone. METHODS:GETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed adenocarcinoma of the prostate (but no previous androgen suppression or pelvic radiotherapy), stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx according to the tumour, node, metastasis (TNM) staging system, whose prostate-specific antigen (PSA) concentration increased from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL after radical prostatectomy, without evidence of clinical disease. Patients were assigned through central randomisation (1:1) to short-term androgen suppression (subcutaneous injection of 10·8 mg goserelin on the first day of irradiation and 3 months later) plus radiotherapy (3D conformal radiotherapy or intensity modulated radiotherapy of 66 Gy in 33 fractions, 5 days a week for 7 weeks) or radiotherapy alone. Randomisation was stratified using a permuted block method (block sizes of two and four) according to investigational site, radiotherapy modality, and prognosis. The primary endpoint was progression-free survival in the intention-to-treat population. This post-hoc one-shot data collection done 4 years after last data cutoff included patients who were alive at the time of the primary analysis and updated long-term patient status by including dates for first local progression, metastatic disease diagnosis, or death (if any of these had occurred) or the date of the last tumour evaluation or last PSA measurement. Survival at 120 months was reported. Late serious adverse effects were assessed. This trial is registered on ClinicalTrials.gov, NCT00423475. FINDINGS: Between Oct 19, 2006, and March 30, 2010, 743 patients were randomly assigned, 374 to radiotherapy alone and 369 to radiotherapy plus goserelin. At the time of data cutoff (March 12, 2019), the median follow-up was 112 months (IQR 102-123). The 120-month progression-free survival was 64% (95% CI 58-69) for patients treated with radiotherapy plus goserelin and 49% (43-54) for patients treated with radiotherapy alone (hazard ratio 0·54, 0·43-0·68; stratified log-rank test p<0·0001). Two cases of secondary cancer occurred since the primary analysis, but were not considered to be treatment related. No treatment-related deaths occurred. INTERPRETATION: The 120-month progression-free survival confirmed the results from the primary analysis. Salvage radiotherapy combined with short-term androgen suppression significantly reduced risk of biochemical or clinical progression and death compared with salvage radiotherapy alone. The results of the GETUG-AFU 16 trial confirm the efficacy of androgen suppression plus radiotherapy as salvage treatment in patients with increasing PSA concentration after radical prostatectomy for prostate cancer. FUNDING: The French Health ministry, AstraZeneca, la Ligue Contre le Cancer, and La Ligue de Haute-Savoie.
Authors: Ashesh B Jani; Eduard Schreibmann; Subir Goyal; Raghuveer Halkar; Bruce Hershatter; Peter J Rossi; Joseph W Shelton; Pretesh R Patel; Karen M Xu; Mark Goodman; Viraj A Master; Shreyas S Joshi; Omer Kucuk; Bradley C Carthon; Mehmet A Bilen; Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Vishal R Dhere; David M Schuster Journal: Lancet Date: 2021-05-07 Impact factor: 79.321
Authors: Jeremie Calais; Wesley R Armstrong; Amar U Kishan; Kiara M Booker; Thomas A Hope; Wolfgang P Fendler; David Elashoff; Nicholas G Nickols; Johannes Czernin Journal: Eur Urol Focus Date: 2020-12-30
Authors: Fabio Zattoni; Isabel Heidegger; Veeru Kasivisvanathan; Alexander Kretschmer; Giancarlo Marra; Alessandro Magli; Felix Preisser; Derya Tilki; Igor Tsaur; Massimo Valerio; Roderick van den Bergh; Claudia Kesch; Francesco Ceci; Christian Fankhauser; Giorgio Gandaglia Journal: Front Surg Date: 2021-07-09
Authors: Robert T Dess; Yilun Sun; William C Jackson; Neil K Jairath; Amar U Kishan; David G Wallington; Brandon A Mahal; Bradley J Stish; Zachery S Zumsteg; Robert B Den; William A Hall; Laila A Gharzai; Elizabeth M Jaworski; Zachary R Reichert; Todd M Morgan; Rohit Mehra; Edward M Schaeffer; Oliver Sartor; Paul L Nguyen; William Robert Lee; Seth A Rosenthal; Jeff M Michalski; Matthew J Schipper; James J Dignam; Thomas M Pisansky; Anthony L Zietman; Howard M Sandler; Jason A Efstathiou; Felix Y Feng; William U Shipley; Daniel E Spratt Journal: JAMA Oncol Date: 2020-05-01 Impact factor: 31.777